We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) ...

Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

Compass Pathways (CMPS) stock rises as the company posts new late-stage trial data for its psychedelic therapy COMP360 ...

Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

COMPASS Pathways stock has delivered a very strong 1 year return, yet its current valuation checks and market multiples point ...

Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

Compass Pathways (NASDAQ: CMPS) is not your typical healthcare company. The London-based clinical-stage biopharma is developing therapies for various forms of depression that center around psilocybin, ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...